Psoriasis Therapeutics Market Size & Share, by Route of Administration (Oral, Parenteral, Topical); Drug Class; Treatment Modality; Type; Distribution Channel - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2026-2035

Psoriasis Therapeutics Market - Regional Analysis

North America Market Insight

North America market is expected to hold the highest market share with 41% market share within the forecast period due to government initiatives and the healthcare system. Government initiatives are elevating patient care and inclusion, along with increasing disease awareness, which provides a strong marketing opportunity for the psoriasis treatments. The presence of major pharmaceutical players and advanced healthcare infrastructure further accelerates product development and rapid commercialization in the region. Additionally, favorable reimbursement policies and widespread adoption of specialty dermatology services continue to reinforce North America's leadership in the global market.

U.S. is driven by increased cases of psoriasis and psoriatic arthritis, broader regulatory approvals for emerging biologics and small molecule therapies, and increased use of telemedicine. The sustained growth of the market could be attributed to increased patient awareness, a supportive reimbursement landscape for therapies, and heavy R&D investments. According to a report by NLM August 2023, in the U.S. psoriasis market, systemic treatments, particularly biologics, are primarily used for moderate-to-severe cases involving ≥10% body surface area, due to their superior efficacy. Additionally, topical treatments typically serve as adjunct therapies rather than standalone options for these patients.

The market in Canada is experiencing growth due to the increasing incidence of the disease and the launch of new biologics. As per a report by NLM in June 2025, in retrospective research involving 154 patients with moderate-to-severe plaque psoriasis treated with bimekizumab among seven outpatient dermatology clinics across Canada, it was revealed that 84% of patients were still on bimekizumab, suggesting good adherence and market potential. This high continuation rate highlights both the clinical effectiveness and patient satisfaction with advanced biologic therapies, reinforcing Canada's expanding role in the global psoriasis treatment landscape.

Asia Pacific Market Insight

The Asia-Pacific psoriasis therapeutics market is the fastest-growing and is expected to hold a considerable market share during the forecast period, due to more opportunities with the spread of psoriasis awareness and improvement in healthcare infrastructure, along with more adoption of advanced biologic treatment. Furthering growth in this market is the supply of government schemes and incentives to support research and development. Growing patient demand, together with government initiatives in big countries including India, China, and Japan, is further fueling the growth of the market, establishing the region as one of the fastest-growing markets globally.

The psoriasis therapeutics market in China is rapidly growing due to biologics and emerging small-molecule therapies. According to a report by NLM in May 2024, in an approximate count of 6.3 million people suffering from psoriasis, with roughly 80-90% carrying plaque psoriasis as a subtype, there is an increased demand for systemic treatment in moderate and severe cases. With the increase in funding from both government and private bodies, growing opportunities for R&D look to address the unmet medical needs while fueling market growth.

India has been growing steadily due to increased disease awareness and treatment advancements. As per a study done by NLM in August 2022, out of 207 adults, only 52% of patients reported satisfaction with their current psoriasis therapy, with compliance as low as 35%, and 64% acknowledged that living with plaque psoriasis significantly impacted their lives.  Although biologic treatments work well, yet are expensive, so most patients still use traditional therapies. Increased government support and funding for affordable treatment and clinical guidelines will foster the evolution of market demand, addressing some of its unmet needs and improving disease management in populations of diverse backgrounds.

Europe Market Insight

The psoriasis therapeutics market in Europe is witnessing rapid growth and is expected to hold a steady market share during the forecast period. The market is driven by the increasing use of new-age small-molecule therapies and modern biologics. As per a report by NLM, March 2023, PSO was diagnosed in 301,639 patients in the last 5 years, and it showed that most of the patients were not treated with systemic medications, and only 2% of patients were treated with biologics.  Market expansion is backed by key factors, including a strong healthcare infrastructure, increased patient awareness, and an enabling regulatory framework. Furthermore, increased R&D spending and improved patient accessibility are imperative facets that enhance treatment options and disease control across the region.

UK is witnessing growth in the country, owing to the strong healthcare system and rising application of biologics. The key drivers include ongoing advancements in R&D, supportive governmental initiatives, and heightened patient awareness. PDE4 inhibitors, TNF inhibitors, and interleukin inhibitors are among the drug classes. Additionally, increasing investments in personalized medicine and targeted therapies are enhancing treatment outcomes and patient quality of life. The National Health Service (NHS) plays a crucial role in facilitating access to innovative therapies through reimbursement and patient support programs.

The psoriasis therapeutics market in Germany is increasing as advanced biologics and targeted therapies fulfill complex patient needs and shape the market. The choices in treatment are dominated by considerations of safety, especially in those patients who have comorbidities such as inflammatory bowel disease. Moreover, collaborations between academic institutions and pharmaceutical companies are accelerating the development of new drugs. Growing awareness campaigns are also helping to reduce stigma and encourage earlier diagnosis and treatment adherence across the country.

Historical Demographic and Clinical Characteristics of PSO Patients in Europe

Source: NLM March 2023